Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the management of androgenic disorders in women, highlighting that treatment is generally more effective than recognized, though improvement may take weeks or months to appear.

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.

This study found that Lespedeza cuneata aqueous extract reduced serum dihydrotestosterone levels and 5α-reductase mRNA expression in testosterone-induced prostatic hyperplasia in rats, suggesting potential as a treatment for prostatic hyperplasia.

This study found that activating CB1 receptor signaling in human hair follicles increased stem cell proliferation while reducing differentiated cell survival, suggesting CB1's role as a survival stimulus for epithelial stem cells.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

This review discusses the evaluation of hyperandrogenemia in women and hypogonadism in men across different life stages and presents biomarkers used for diagnosing male hypogonadism, reporting no new clinical results.

In this study, researchers found no significant difference in bladder cancer incidence between men treated with finasteride and those given a placebo, suggesting that reduced dihydrotestosterone levels may not impact bladder cancer risk.

This review discusses the causes and treatment strategies for hirsutism, emphasizing that combination therapy targeting androgen suppression and hair removal techniques is most effective; no new clinical results are reported.

This review discusses the main features of anti-androgen drugs, combined treatments, and insulin sensitizers in managing hirsutism and reports no new research findings.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

This study reports that 4-(alkylthio)- and 4-(arylthio)-benzonitriles showed moderate sebum reduction as androgen receptor antagonists when applied topically in a validated animal model.

This study found that resveratrol significantly alleviated testicular damage in male rats caused by finasteride, which otherwise led to decreased testosterone levels and various histopathological alterations in the testes.

This study reports two distinct patterns of hair changes in postmenopausal women, linking diffuse generalized scalp hair loss to older age and frontal hair loss to higher facial hair scores and younger age.

This case study reports that a virilizing Leydig cell type ovarian tumor in a 40-year-old woman caused hyperandrogenism and virilization symptoms, which improved post-surgery.

In this study, testosterone was reported to increase aquaporin levels and water reabsorption in the kidneys of male rats, potentially leading to higher blood pressure, with effects mitigated by flutamide and finasteride.

This source suggests that migraine prevalence increases in transgender women using oestrogen and decreases in transgender men using testosterone, with high oral oestrogen doses in transgender women potentially linked to aura risk.

This article reviews the classification history of androgenic alopecia and highlights the need for further research to find effective hair growth medications.

This review discusses medical therapies for benign prostatic hyperplasia, highlighting the importance of personalizing treatments to individual patient needs and preferences.

This paper reviews the role of androgens in SARS-CoV-2 infection and their potential impact on disease severity, suggesting androgen-targeting strategies might influence outcomes, but reports no new clinical results.

Minoxidil, a common hair loss treatment, might work by counteracting a hormone that reduces hair growth and promotes hair loss.

This review found that patients taking antiandrogens, 5 alpha-reductase inhibitors, and spironolactone have an increased risk of developing gynecomastia, potentially due to hormonal changes.

In this study, 5α-reductase inhibitors were found to have no significant impact on preventing tumorigenesis or progression in in vitro models of urothelial cancer.

This study found that LHE may prevent and reverse testosterone-induced prostatic hyperplasia, supporting the traditional use of Kigelia africana for some reproductive system disorders.

This article addresses the mechanisms of androgenic alopecia and seeks to clarify misconceptions, but it reports no new empirical findings and calls for further controlled studies.

This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms.

This commentary discusses how common latent viruses might contribute to male-pattern baldness through mechanisms involving transcription factor deficiency and overexpression of specific proteins, based on a concept called microcompetition; it reports no new research results.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This investigation found that certain supplements, particularly whey protein isolate, growth hormones, and anabolic steroids, can negatively impact hair loss by affecting biochemical pathways.

Hormones, especially androgens, play a key role in causing acne, and treatments like hormone control pills and hormone-blocking medications can help.

In a hamster model of COVID-19, this study observed that both low and high doses of testosterone worsened illness in males, while finasteride prevented severe outcomes.